NRS

NRSInsights’ March 2024 Retail Same-Store Sales Report

Retrieved on: 
Monday, April 8, 2024
DMA's, Cooking, POS, National Retail Solutions, SVP, Sale, Tobacco, Foodservice, Commerce, Energy drink, NRS, Alcoholism, Calendar, Cryptocurrency

NEWARK, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- NRSInsights, a provider of sales data and analytics drawn from retail transactions processed through the National Retail Solutions (NRS) point-of-sale (POS) platform, today announced comparative same-store sales results for March 2024.

Key Points: 
  • March same-store sales jumped 7.2% year-over-year, the highest rate of increase since June 2023
    NEWARK, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- NRSInsights , a provider of sales data and analytics drawn from retail transactions processed through the National Retail Solutions (NRS) point-of-sale (POS) platform, today announced comparative same-store sales results for March 2024.
  • (Same-store sales, unit sales, transactions, and average price data throughout this release refer to March 2024 unless otherwise noted.
  • Same-store sales per calendar day in February 2024 had increased 7.4% compared to January 2024.
  • The NRSInsights monthly Same-Store Retail Sales Reports are intended to provide timely topline data reflective of sales at NRS’ network of independent, predominantly urban, retail stores.

Pluri Inc. Announces 1-for-8 Reverse Share Split

Retrieved on: 
Wednesday, March 27, 2024
Indian stock exchange, Biotechnology, Plural, Cell, CUSIP, NRS, PLUR, Nevada Revised Statutes, Security (finance)

After giving effect to the reverse share split of the Company’s Common Shares, each eight (8) Common Shares will be combined into one Common Share, such that the Company’s 41,816,959 Common Shares outstanding will be reduced to approximately 5,227,120 Common Shares outstanding (the “Reverse Share Split”).

Key Points: 
  • After giving effect to the reverse share split of the Company’s Common Shares, each eight (8) Common Shares will be combined into one Common Share, such that the Company’s 41,816,959 Common Shares outstanding will be reduced to approximately 5,227,120 Common Shares outstanding (the “Reverse Share Split”).
  • No fractional shares will be issued as a result of the reverse split as any fractional shares resulting from the reverse split will be rounded up to the nearest whole share on a per shareholder basis.
  • No additional Company or shareholder approval is required because both the number of authorized Common Shares and the number of outstanding Common Shares will be proportionally reduced as a result of the Reverse Share Split, the Reverse Share Split will not adversely affect any other class of shares of the Company and the Company will not pay money or issue scrip to shareholders who would otherwise be entitled to receive a fractional share as a result of the reverse split.
  • The reverse split will not impact any shareholder's percentage ownership of Pluri or voting power, except for minimal effects resulting from the treatment of fractional shares.

InnoCare Releases 2023 Results and Business Highlights

Retrieved on: 
Thursday, March 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, QD, Tafasitamab, Patient, B-cell lymphoma, NDA, SLE, POC, IND, Clinical trial, Bone marrow, IKZF1, Phase, Therapy, IGA, MCD, Dexamethasone, MCL, Neuromyelitis optica spectrum disorder, IKZF3, AML, NMOSD, Outline of health sciences, DLT, Cancer, Autoimmune disease, Safety, TYK2, HSA, NRDL, BLA, Follicular lymphoma, Food, GC, Development, Multiple sclerosis, PD, CRBN, Public, Gordon Ramsay's Bank Balance, Multiple myeloma, ITP, BCL2, Leukemia, Cmax, Gadolinium, HKEX, SRI, AAD, Proteinuria, DLBCL, Glucocorticoid, IVIG, Loss, European Hematology Association, American Academy, EHA, Lenalidomide, NHL, Non-Hodgkin lymphoma, CCR8, US FDA, BTK, NRS, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.
  • In 2023, InnoCare has continued to advance its robust pipeline across various clinical stages, continuously unleashing the power of innovation to meet unmet medical needs.
  • In June 2023, the ITP Phase II result was orally presented at the European Hematology Association (EHA) 2023 Hybrid Congress.
  • InnoCare was approved by the Hong Kong Stock Exchange to remove "B" from the stock code from May 12, 2023.

Latest data of InnoCare's ICP-332 for the Treatment of Atopic Dermatitis Presented at LBA Session of 2024 AAD

Retrieved on: 
Wednesday, March 13, 2024
High, Safety, HKEX, AAD, IGA, Patient, TYK2, Trial of the century, NRS, American Academy, Pharmaceutical industry

75 eligible AD patients were randomized into three groups: once daily oral ICP-332 80 mg, once daily oral 120 mg, and placebo respectively.

Key Points: 
  • 75 eligible AD patients were randomized into three groups: once daily oral ICP-332 80 mg, once daily oral 120 mg, and placebo respectively.
  • ICP-332 demonstrated a rapid response, with the NRS score from baseline in the two treatment groups showing statistically significant improvement on day 2.
  • With the improvement of pruritus, the quality of life of subjects in the two treatment groups was significantly elevated.
  • The 2024 AAD Annual Meeting is held from March 8 to 12 in San Diego, California, USA.

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Retrieved on: 
Wednesday, February 21, 2024
Freedom, Recurrence, Scar, Inflammation, FDA, Quality of life, TSX, C-reactive protein, Pericardial fluid, Pericarditis, Viral, CRDL, Safety, Pericardium, Therapy, Chronic pain, Fatigue, Length of stay, Patient, News, Heart, Hospital, Research, NRS

Topline Results Expected in Q2 2024

Key Points: 
  • "Having achieved full patient enrollment, we are now positioned to announce high-level MAvERIC-Pilot clinical trial data in the second quarter of this year.
  • MAvERIC-Pilot (NCT05494788) is a Phase II open-label pilot study investigating the tolerance, safety, and effect of CardiolRx™ administered to patients with recurrent pericarditis.
  • The NRS is a validated clinical tool employed across multiple conditions with acute and chronic pain, including previous studies of recurrent pericarditis.
  • The only FDA-approved therapy for recurrent pericarditis, launched in 2021, is costly and is primarily used as a third-line intervention.

NRSInsights’ February 2024 Retail Same-Store Sales Report

Retrieved on: 
Friday, March 8, 2024
Weather, National Retail Solutions, POS, SVP, Leap year, Commerce, Sale, Foodservice, DMA's, Tobacco, Sparkling, NRS, Cryptocurrency

NEWARK, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- NRSInsights, a provider of sales data and analytics drawn from retail transactions processed through the National Retail Solutions (NRS) point-of-sale (POS) platform, today announced comparative same-store sales results for February 2024.

Key Points: 
  • NEWARK, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- NRSInsights , a provider of sales data and analytics drawn from retail transactions processed through the National Retail Solutions (NRS) point-of-sale (POS) platform, today announced comparative same-store sales results for February 2024.
  • (Same-store sales, unit sales, transactions, and average price data refer to February 2024 unless otherwise noted.
  • Same-store sales increased 7.4% compared to January 2024, consistent with the expected seasonal rebound from the post-holiday dip in January.
  • The NRSInsights monthly Same-Store Retail Sales Reports are intended to provide timely topline data reflective of sales at NRS’ network of independent, predominantly urban, retail stores.

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, February 28, 2024
Alkaline phosphatase, Acquisition, Liver, Child, Therapy, EMA, Ursodeoxycholic acid, New Drug Application, Gilead Sciences, Education, IDEAL, FDA, Science, Quality of life, Food, Marketing, U.S. FDA, Breakthrough, ALP, Hospital, PBC, Phase 3, Cirrhosis, Hepatology, Seladelpar, Safety, ULN, European Medicines Agency, Numerical, Patient, MHRA, UDCA, Itch, NDA, NRS, Pharmaceutical industry

NEWARK, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year and fourth quarter ended December 31, 2023.

Key Points: 
  • NEWARK, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year and fourth quarter ended December 31, 2023.
  • “2023 was a seminal year for CymaBay with critical achievements in the development of our investigational therapeutic, seladelpar.
  • Net loss for the year ended December 31, 2023 and 2022 was $105.4 million and $106.0 million, or ($0.99) and ($1.21) per share, respectively.
  • Net loss for the three months ended December 31, 2023 was higher than the three months ended December 31, 2022 primarily due to higher operating expenses.

NRS Digital Media Launches StrataSelect

Retrieved on: 
Monday, February 26, 2024
Advertising, Tobacco, Consumer, National Retail Solutions, POS, NRS, DMA's

NEWARK, NJ, Feb. 26, 2024 (GLOBE NEWSWIRE) -- NRS Digital Media, a division of National Retail Solutions (NRS), today launched StrataSelect, an in-store retail digital media planning solution that enables brands to achieve data-driven, value-based, store targeting across more than 28,000 NRS digital screens hosted by an independent retailers nationwide. 

Key Points: 
  • NEWARK, NJ, Feb. 26, 2024 (GLOBE NEWSWIRE) -- NRS Digital Media, a division of National Retail Solutions (NRS), today launched StrataSelect, an in-store retail digital media planning solution that enables brands to achieve data-driven, value-based, store targeting across more than 28,000 NRS digital screens hosted by an independent retailers nationwide.
  • In contrast, StrataSelect utilizes a proprietary computational process to analyze diverse data sets including store-specific NRS retailer scan data, demographics, consumer behavior, geographic trends, and category and brand purchase data.
  • “StrataSelect transforms traditional media planning strategies by leveraging a detailed, contextual analysis of each of our retail stores’ customers,” said Eli Korn, Chief Operating Officer of NRS.
  • StrataSelect is another way that NRS Digital Media innovation empowers our advertising partners to achieve success in every campaign.”
    Explore the limitless possibilities of targeted store selection with NRS Digital Media’s StrataSelect by contacting Brandon Thurber ( [email protected] ) Vice President - Data Sales & Client Success, or Esther Hebbard ( [email protected] ) Sr. Director - Advertising Sales.

THE CENTER FOR DISCOVERY'S 24TH ANNUAL EVENING OF DISCOVERY GALA TO HONOR TCFD BOARD CHAIR EDWARD C. SWEENEY

Retrieved on: 
Tuesday, February 20, 2024
Bear Stearns, Catholic Church, Autism spectrum, TCFD, CIT Group, SVP, National Retail Systems, Music therapy, Transport, Rockville Centre, New York, ASD, Hofstra University, Chairperson, Cipriani S.A., Morgan Stanley, Recreation, Improper integral, Barclays, NRS, Education, Nursing

HARRIS, N.Y., Feb. 20, 2024 /PRNewswire/ -- The Center for Discovery (TCFD, The Center) announced today that TCFD Board Chair, Edward C. Sweeney, will be honored at its upcoming Evening of Discovery Gala. The annual event will be held on Tuesday, May 7th, 2024 at Cipriani 42nd street in New York City.

Key Points: 
  • The NYC Event is set for May 7th, 2024
    HARRIS, N.Y., Feb. 20, 2024 /PRNewswire/ -- The Center for Discovery (TCFD, The Center) announced today that TCFD Board Chair, Edward C. Sweeney, will be honored at its upcoming Evening of Discovery Gala.
  • "We are thrilled to celebrate Ed Sweeney as our 2024 Evening of Discovery Honoree," said Dr. Terry Hamlin , President and CEO of The Center.
  • The Center for Discovery's last in-person Evening of Discovery Gala was held in 2019.
  • Co-chairs of the Evening of Discovery Gala are Monica Belag Forman, Terry Manzione, Elizabeth Bracco Quinn, Maura Robinson, and Emily Gerson Saines.

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Retrieved on: 
Thursday, February 15, 2024
Fast Track, Recurrence, Scar, Inflammation, FDA, Quality of life, TSX, C-reactive protein, Myocarditis, Pericardial fluid, Pericarditis, Viral, CRDL, ODD, Safety, Pericardium, Therapy, Chronic pain, Fatigue, Length of stay, Patient, News, Disease, Heart, Hospital, Research, NRS, Priority review, Pharmaceutical industry

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II Study

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the United States Food and Drug Administration ("FDA") has granted Orphan Drug Designation ("ODD") for the Company's lead small molecule drug candidate for the treatment of pericarditis, which includes recurrent pericarditis.
  • MAvERIC-Pilot (NCT05494788) is a Phase II open-label pilot study investigating the tolerance, safety, and effect of CardiolRx™ administered to patients with recurrent pericarditis.
  • The NRS is a validated clinical tool employed across multiple conditions with acute and chronic pain, including previous studies of recurrent pericarditis.
  • The only FDA-approved therapy for recurrent pericarditis, launched in 2021, is costly and is primarily used as a third-line intervention.